Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer | Podcast S2 E39

TSN POdcast

Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. talks KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here.